Here is the relevant passage in Washburne piece:
The DEFUSE proposal
We’ve gone over the geographic and genomic evidence that makes SARS-CoV-2 highly unusual among other SARS coronaviruses. SARS-CoV-2 emerged in Wuhan in 2019 far from the hotspots of wildlife coronavirus diversity, right next door to world leading labs studying wildlife coronaviruses, and it emerged with a human-specific furin cleavage site and the restriction map of an infectious clone.
Less than 1.5 years earlier, researchers at the Wuhan Institute of Virology and elsewhere proposed to insert a human-specific furin cleavage site in a SARS coronavirus in Wuhan.
Read those last two paragraphs again.
The DEFUSE proposal is where researchers laid out their intentions to make a virus shockingly similar to SARS-CoV-2 in all of the ways in which SARS-CoV-2 is glaringly different from wildlife SARS coronaviruses.
The DEFUSE proposal was a grant proposal written by Peter Daszak at EcoHealth Alliance in NYC (EHA), Zheng-Li Shi at the Wuhan Institute of Virology (WIV), Ralph Baric at the University of North Carolina (UNC), Linfa Wang at Duke-NUS Singapore, and others. The proposal was submitted to DARPA’s PREEMPT call, a grant call looking for innovative ideas to preempt pathogen spillover before it occurs.
The DEFUSE proposal contained many specific aims: catching bats, sending samples from bats to labs, looking for viruses in the samples, studying and modifying the viruses in labs, developing raccoon poxvirus vaccines to boost immunity & protect bats against the viruses, testing the viruses + immune-boosting in bats, forecasting where spillover is most likely to occur, and deploying vaccines in wild bats to preempt spillover.
If you look on page 11 of the main document, page 13 of the online PDF above, under the section labelled “S2 proteolytic cleavage and glycosylation sites”, you can find the most important passage in this document.
The researchers propose to scan SARS-CoV genomes for potential furin cleavage sites and, where none exist, they propose to insert the appropriate cleavage sites. Specifically, they say:
”… we will introduce appropriate human-specific cleavage sites and evaluate growth potential in Vero and HAE cells”